Viral Hepatitis B
Walsh AM & Grimes JA: Hepatitis B. In: Domino, FJ, ed. The 5-Minute Clinical Consult 2012, 20th ed. Lippincott Williams & Wilkins, Philadelphia, PA, 2012, pp 580-581.
Workowski KA, Berman S, & Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59(RR-12):1-110.
Advisory Committee on Immunization Practices (ACIP) : Recommended adult immunization schedule: United States, 2010. Ann Intern Med 2010; 152(1):36-39.
American College of Obstetricians and Gynecologists : ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol 2007; 110(4):941-956.
Centers for Disease Control and Prevention: Recommended Immunization Schedules for Persons Aged 0 Through 18 Years — United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 58(51-52):1-4.
Centers for Disease Control and Prevention: Recommended Adult Immunization Schedule - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59(1):29-32.
Cooke GS, Main J, & Thursz MR: Treatment for hepatitis B. BMJ 2010; 340:b5429.
Dienstag JL: Hepatitis B virus infection. N Engl J Med 2008; 359(14):1486-1500.
Keeffe EB , Dieterich DT , Han SH , et al: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6(12):1315-1341.
Lok AS & McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009; 50(3):661-662.
Mast EE, Weinbaum CM, Fiore AE, et al: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55(RR-16):1-33.
Mast EE, Margolis HS, Fiore AE, et al: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54(RR-16):1-31.
National Institute for Health and Clinical Excellence: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B. National Institute for Health and Clinical Excellence. London, United Kingdom. 2006. Available from URL: http://guidance.nice.org.uk/TA96/Guidance/pdf/English. As accessed 2010-05-04.
Pungpapong S , Kim WR , & Poterucha JJ : Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007; 82(8):967-975.
Rao W , Wu X , & Xiu D : Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 2009; 22(4):387-394.
Shamliyan TA , MacDonald R , Shaukat A , et al: Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009; 150(2):111-124.
Shiffman ML : Management of acute hepatitis B. Clin Liver Dis 2010; 14(1):75-91.
Sorrell MF, Belongia EA, Costa J, et al: National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009; 150(2):104-110.
U.S. Preventive Services Task Force: Screening for Hepatitis B Virus Infection in Pregnancy. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality. Rockville, MD. 2009. Available from URL: http://www.ahrq.gov/clinic/uspstf/uspshepbpg.htm. As accessed 2010-05-10.
Weinbaum CM, Williams I, Mast EE, et al: Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57(RR-8):1-20.
© 2015 Truven Health Analytics Inc. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. All illustrations and images included in CareNotes® are the copyrighted property of A.D.A.M., Inc. or Truven Health Analytics.
The above information is an educational aid only. It is not intended as medical advice for individual conditions or treatments. Talk to your doctor, nurse or pharmacist before following any medical regimen to see if it is safe and effective for you.